About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Eli Lilly (NYSE: LLY) Acquires DICE Therapeutics (NASDAQ: DICE): A New Step in Autoimmune Disease Treatments

Eli Lilly and Company (NYSE: LLY) has announced a definitive agreement to acquire DICE Therapeutics, Inc. (NASDAQ: DICE), a biopharmaceutical company known for its DELSCAPE technology platform and oral therapeutic candidates. This strategic acquisition aims to expedite the development of novel treatments for chronic autoimmune diseases.

Eli Lilly and DICE Therapeutics: A Perfect Synergy

Patrik Jonsson, an executive at Eli Lilly, lauded the innovation, talent, and drug discovery expertise of DICE Therapeutics. DICE’s specialization in oral IL-17 inhibitors could prove instrumental in addressing significant unmet medical needs.

DICE’s Novel Approach to Drug Discovery

Kevin Judice, CEO of DICE Therapeutics, expressed optimism for the future, specifically regarding their pipeline of IL-17 inhibitors DC-806 and DC-853. DICE’s unique approach to discovering and advancing oral, small molecules for protein-protein interaction targets will now benefit from Lilly’s industry-leading clinical development capabilities.

Acquisition Details

Lilly will initiate a tender offer to acquire all outstanding shares of DICE at $48 per share in cash, totaling approximately $2.4 billion. This represents a premium of about 40% to the 30-day volume-weighted average trading price of DICE’s common stock as of June 16, 2023.

The transaction is expected to close in the third quarter of 2023, pending standard closing conditions. Once the tender offer concludes, any remaining shares of DICE will be purchased through a second-step merger at the same price.

About DICE Therapeutics

DICE Therapeutics is a biopharmaceutical company renowned for its innovative DELSCAPE technology platform. It focuses on developing oral therapeutics for chronic immunological and other diseases. Their lead therapeutic candidates target IL-17, a pro-inflammatory signaling molecule implicated in numerous immunology indications. They’re also working on oral therapeutic candidates targeting integrin α4ß7 for treating inflammatory bowel disease.

Incorporating this transaction into Eli Lilly’s financial guidance and results will happen according to Generally Accepted Accounting Principles (GAAP). Eli Lilly will determine whether to treat this transaction as a business combination or an asset acquisition, including any associated in-process research and development charges, upon closing. Legal counsel for this transaction includes Kirkland & Ellis LLP for Lilly and Centerview Partners LLC and Fenwick & West LLP for DICE.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Eli Lilly (NYSE: LLY) Acquires DICE Therapeutics (NASDAQ: DICE): A New Step in Autoimmune Disease Treatments appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.